Balaji Amines Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance (Consolidated)

Q2 FY27 Results:

  • Total Revenue: ₹472 crore (vs. ₹348 crore in Q2FY26)
  • EBITDA: ₹106 crore (vs. ₹67 crore in Q2FY26)
  • EBITDA Margin: 22% (vs. 19% in Q2FY26)
  • PAT: ₹67 crore (vs. ₹37 crore in Q2FY26)
  • PAT Margin: 14% (vs. 11% in Q2FY26)
  • Cash PAT: ₹86 crore (vs. ₹57 crore in Q2FY26)
  • Cash PAT Margin: 18% (vs. 16% in Q2FY26)
  • Sales Volume: 24,491 MT (vs. 26,165 MT in Q2FY26)
  • Diluted EPS: ₹20.76 per equity share (vs. ₹10.67 in Q2FY26)

H1 FY27 Results:

  • Total Revenue: ₹933 crore (vs. ₹715 crore in H1FY26)
  • EBITDA: ₹227 crore (vs. ₹131 crore in H1FY26)
  • EBITDA Margin: 24% (vs. 18% in H1FY26)
  • PAT: ₹146 crore (vs. ₹74 crore in H1FY26)
  • PAT Margin: 16% (vs. 10% in H1FY26)
  • Cash PAT: ₹183 crore (vs. ₹109 crore in H1FY26)
  • Cash PAT Margin: 20% (vs. 15% in H1FY26)

Volume Breakdown for Q2FY27

  • Amines volumes: 6,525 MT
  • Amines Derivatives volumes: 8,974 MT
  • Specialty Chemicals volumes: 8,992 MT

Standalone Performance

On a standalone basis, the company reported:

  • Q2FY27 Revenue: ₹434 crore (vs. ₹316 crore in Q2FY26)
  • Q2FY27 EBITDA: ₹103 crore (vs. ₹57 crore in Q2FY26)
  • Q2FY27 PAT: ₹69 crore (vs. ₹31 crore in Q2FY26)
  • The company maintains zero debt on a standalone basis.

Expansion and Growth Initiatives

The company highlighted several expansion projects:

1. Acetonitrile (ACN) Facility: Commercial production commenced at the expanded facility with increased installed capacity to 1,440 TPM (Tonnes Per Month).

2. Dimethyl Ether (DME) Plant: Successfully commissioned India's first commercial-scale DME plant with 100,000 TPA capacity. DME Road Tanker valves approved after rigorous testing by PESO.

3. Upcoming Products: N-Methyl Morpholine (NMM) planned for commercialization to expand specialty chemicals portfolio.

4. Balaji Speciality Chemicals Expansion:

  • Unit-I brownfield expansion (EDA derivatives including DETA, TETA, Piperazine, AEEA, and AEP) on track for commissioning at the end of FY27
  • Unit-II greenfield project at MIDC, Chincholi (manufacturing HCN, NaCN, EDTA, and EDTA-2Na) targeted for commissioning in Q4 FY27

Management Commentary

Mr. D. Ram Reddy, Managing Director, commented that Q2 FY27 reflected resilient execution and steady progress on strategic priorities. The company has improved the process of Di Isopropylamine (DIPA) through continuous efforts. While volumes were affected by external factors, the company leveraged its strength in stabilizing the product portfolio to maintain top-line stability and strengthen the bottom line.

The focus for H2 FY27 is on driving higher utilization, improving operating efficiencies, and translating recent investments into stronger earnings growth. The company remains confident in its ability to drive sustainable growth and create long-term value for shareholders.

Additional Information

The company operates four manufacturing sites (three near Solapur and one near Hyderabad) and a fully furnished Laboratory for product development. It also operates a 5-star hotel in Solapur - Balaji Sarovar, managed by the Sarovar group.

Investor Relations Contacts

  • Investor Relations Advisors: MUFG Intime India Private Limited
  • Mr. Nikunj Seth: nikunj.seth@in.mpms.mufg.com
  • Ms. Sakshi Mehta: sakshi.mehta@in.mpms.mufg.com